{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/","result":{"pageContext":{"chapter":{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH","depth":2,"htmlHeader":"<!-- begin field d3758322-7495-49a6-a5eb-fdfa35d5318d --><h2>Scenario: Management of adults with heterozygous familial hypercholesterolaemia</h2><!-- end field d3758322-7495-49a6-a5eb-fdfa35d5318d -->","summary":"Covers the management of adults with heterozygous familial hypercholesterolaemia (FH) confirmed by a specialist.","htmlStringContent":"<!-- begin item 0250944d-22e5-47a9-b7cb-07cc7026388c --><!-- begin field 4a440b07-4574-4d2e-a3fb-acd900ade2dc --><p>From age 15 years onwards.</p><!-- end field 4a440b07-4574-4d2e-a3fb-acd900ade2dc --><!-- end item 0250944d-22e5-47a9-b7cb-07cc7026388c -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"df3c3a29-c315-5f0a-a1f2-d819fb11a670","slug":"management-of-adults-with-confirmed-heterozygous-fh","fullItemName":"Management of adults with confirmed heterozygous FH","depth":3,"htmlHeader":"<!-- begin field dad0412d-5cb7-4854-b526-5b08e076d6ea --><h3>How should I manage an adult with confirmed heterozygous familial hypercholesterolaemia?</h3><!-- end field dad0412d-5cb7-4854-b526-5b08e076d6ea -->","summary":null,"htmlStringContent":"<!-- begin item 847e7696-aa41-44f7-aa0d-122bce1452a5 --><!-- begin field 74b5e583-e8c5-405c-96c6-aa6b00d0ef06 --><p><strong>Do <em>not </em>use coronary heart disease (CHD) risk assessment tools, such as QRISK and those based on the Framingham algorithm, to guide management because people with familial hypercholesterolaemia (FH) are already at a high risk of premature CHD.</strong></p><ul><li><strong>Refer people who are at <em>very high risk </em>of a coronary event to a specialist with expertise in FH. </strong><ul><li>Very high risk is defined as the presence of any of the following:<ul><li>Established CHD.</li><li>A family history of premature CHD (first-degree relative [parent, sibling, or child] before 60 years of age or second-degree relative [grandparent, uncle, or aunt] before 50 years of age).</li><li>Two or more other cardiovascular disease (CVD) risk factors (such as male gender, smoking, hypertension, or diabetes).</li></ul></li></ul></li><li><strong>Consider a routine referral to a cardiologist for evaluation for possible CHD </strong>if the person has a family history of CHD in early adulthood.</li><li><strong>For all other adults with confirmed heterozygous FH:</strong><ul><li>Consider doing a baseline electrocardiogram (ECG).</li><li>Implement measures to reduce the risk of CVD, including: <ul><li>Addressing other modifiable CVD risk factors, such as smoking, high blood pressure, and obesity. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li>Offering individualized nutritional advice from a dietician. Do not advise against the consumption of food products containing stanols and sterols. If people with FH wish to consume them, advise that such products cannot be prescribed, and they need to be taken consistently to be effective.</li><li>Identifying and managing secondary causes of hyperlipidaemia, such as excess alcohol consumption, uncontrolled diabetes mellitus, hypothyroidism, liver disease, nephrotic syndrome, and chronic kidney disease. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>,  <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a>, <a class=\"topic-reference external-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/\">Non-alcoholic fatty liver disease (NAFLD)</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>.</li><li>Where possible, optimizing treatment of other conditions associated with an increased risk of CVD, including atrial fibrillation; rheumatoid arthritis, systemic lupus erythematosus, and other systemic inflammatory disorders; and serious mental health problems. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/rheumatoid-arthritis/\">Rheumatoid arthritis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/psychosis-schizophrenia/\">Psychosis and schizophrenia</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/bipolar-disorder/\">Bipolar disorder</a>.</li></ul></li><li>Perform <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#tests-before-drug-treatment\">baseline blood tests</a> to determine the suitability of treatment with a lipid-modifying drug.<ul><li>If appropriate, prescribe a <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#lipid-modification-treatment-in-adults-with-heterozygous-fh\">lipid-modifying drug</a>.</li></ul></li></ul></li><li><strong>Provide written information on FH, for example:</strong><ul><li>HEART UK (<a href=\"http://www.heartuk.org.uk/\" data-hyperlink-id=\"a8dab051-9a6b-474e-869e-aa6b0174cfc5\">www.heartuk.org.uk</a>) has an <a href=\"https://www.heartuk.org.uk/downloads/health-professionals/publications/familial-hypercholesterolaemia.pdf\" data-hyperlink-id=\"ef723600-4cc1-423d-93db-aa0200c1c21c\">educational booklet</a> for people with FH.</li></ul></li><li><strong>Offer advice on support groups, </strong>for example:<ul><li>HEART UK (<a href=\"http://www.heartuk.org.uk/\" data-hyperlink-id=\"ac1084fb-d0a1-422d-9b20-a98d002f8f2b\">www.heartuk.org.uk</a>, telephone 0845 450 5988) provides information and advice on preventing premature deaths caused by high cholesterol concentrations.</li></ul></li></ul><!-- end field 74b5e583-e8c5-405c-96c6-aa6b00d0ef06 --><!-- end item 847e7696-aa41-44f7-aa0d-122bce1452a5 -->","subChapters":[{"id":"59a70bd6-c341-580c-a697-f9417479ae0d","slug":"basis-for-recommendation-123","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3473719b-2ccd-44ff-9c23-3c454b805fa6 --><h4>Basis for recommendation</h4><!-- end field 3473719b-2ccd-44ff-9c23-3c454b805fa6 -->","summary":null,"htmlStringContent":"<!-- begin item 12379468-49d2-477f-93f0-d4d1f2cdc292 --><!-- begin field 2aae640e-24fa-469d-9759-6b5ec0c826f6 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guidelines <em>Identification and management of familial hypercholesterolaemia (Full guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>] and <em>Familial hypercholesterolaemia: identification and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>]<em>.</em></p><ul><li><strong>Measures to reduce the risk of cardiovascular disease (CVD)</strong><ul><li>These recommendations are extrapolated from the NICE guideline <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>], which makes recommendations on CVD risk reduction following cardiovascular risk assessment using the QRISK assessment tool. For more information, see the sections on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/management/cvd-risk-less-than-10percent/#lifestyle-advice\">Lifestyle advice</a> and <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/management/cvd-risk-less-than-10percent/#managing-comorbidities\">Managing comorbidities</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li><li>Be aware that coronary heart disease (CHD) risk assessment tools, such as QRISK and those based on the Framingham algorithm, should not be used to guide management in people with familial hypercholesterolaemia (FH) because they are already at a high risk of premature CHD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>].</li></ul></li></ul><!-- end field 2aae640e-24fa-469d-9759-6b5ec0c826f6 --><!-- end item 12379468-49d2-477f-93f0-d4d1f2cdc292 -->","subChapters":[]}]},{"id":"68bd496e-f817-5b49-a6d6-2e62d32f7064","slug":"lipid-modification-treatment-in-adults-with-heterozygous-fh","fullItemName":"Lipid-modification treatment in adults with heterozygous FH","depth":3,"htmlHeader":"<!-- begin field 3999ac30-d0d4-444f-bd3f-f356b3e164ef --><h3>Which lipid-modifying drug should I offer an adult with heterozygous familial hypercholesterolaemia?</h3><!-- end field 3999ac30-d0d4-444f-bd3f-f356b3e164ef -->","summary":null,"htmlStringContent":"<!-- begin item 9f8adac0-6c3b-4436-a9d1-f4c5be3f2d69 --><!-- begin field f6c67cfa-772e-48bc-a7cc-f2bdf6c0bc61 --><ul><li><strong>For all other adults with confirmed heterozygous </strong><strong>familial hypercholesterolaemia (FH)</strong><strong><strong>,</strong> </strong>offer a <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#basis-for-recommendation-a2e\">high-intensity statin</a> as the initial treatment, and aim to achieve at least a 50% reduction in low-density lipoprotein (LDL) cholesterol concentration from the baseline measurement. <ul><li>Before initiating treatment with a statin, perform <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#tests-before-drug-treatment\">baseline blood tests</a> to ensure that lipid-modification treatment is appropriate.</li><li>If appropriate, prescribe a daily dose of atorvastatin 20 mg or rosuvastatin 10 mg, unless statins are contraindicated (for example during pregnancy). <ul><li>Prescribe atorvastatin 20 mg (and not rosuvastatin 10 mg) for people with predisposing factors for rhabdomyolysis, such as being of Asian origin, concomitant use with an <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/statins-atorvastatin-rosuvastatin-simvastatin/#drug-interactions\">interacting</a> drug, and stage 3 chronic kidney disease (estimated glomerular filtration rate 30–60 mL/minute/1.73 m<sup>2</sup>).</li><li>For detailed information on prescribing statins, including contraindications and cautions, adverse effects, and drug interactions, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/statins-atorvastatin-rosuvastatin-simvastatin/\">Prescribing information</a>.</li></ul></li><li>Advise the person that lipid-modification treatment should be lifelong.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#follow-up\">Follow up</a> the person to assess the efficacy and tolerability of treatment.</li></ul></li><li><strong>If statins are contraindicated, consider one of the following options:</strong><ul><li>Prescribe ezetimibe 10 mg once daily (provided creatine kinase and liver function tests are normal and ezetimibe is not contraindicated). For detailed information on prescribing ezetimibe, including contraindications and cautions, adverse effects, and drug interactions, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/ezetimibe/\">Ezetimibe</a>.</li><li>Refer to a specialist with expertise in FH.</li></ul></li><li><strong>If both statins and ezetimibe are contraindicated, </strong>refer to a specialist with expertise in FH. Secondary care treatment options include:<ul><li>A bile acid sequestrant (resin) or a fibrate.</li><li>A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (alirocumab or evolocumab). See the National Institute for Health and Care (NICE) technology appraisal guidance on <a data-hyperlink-id=\"c079643e-8591-4eb2-896c-a9fa00f062d5\" href=\"https://www.nice.org.uk/guidance/ta393/chapter/1-Recommendations\">Alirocumab</a> and <a data-hyperlink-id=\"8186488d-532a-4324-9ef4-a9fa00f0630c\" href=\"https://www.nice.org.uk/guidance/ta394/chapter/1-Recommendations\">Evolocumab</a> for more informaton on these treatments. </li></ul></li></ul><!-- end field f6c67cfa-772e-48bc-a7cc-f2bdf6c0bc61 --><!-- end item 9f8adac0-6c3b-4436-a9d1-f4c5be3f2d69 -->","subChapters":[{"id":"716422ba-0fe9-591d-9eb0-bef9747c5fe9","slug":"tests-before-drug-treatment","fullItemName":"Tests before drug treatment","depth":4,"htmlHeader":"<!-- begin field 9e049900-8d06-4831-8548-aa0200cc3bea --><h4>What tests should I perform before starting lipid-modification treatment?</h4><!-- end field 9e049900-8d06-4831-8548-aa0200cc3bea -->","summary":null,"htmlStringContent":"<!-- begin item 14912e4d-96ff-4de1-92cd-aa0200cc3bd5 --><!-- begin field cce35e77-0a70-4aff-b2b2-aa0200cc3bea --><p><strong>Perform the following baseline blood tests to ensure that lipid-modification treatment is suitable for the person:</strong></p><ul><li><strong>Creatine kinase (CK) </strong>—<strong> </strong>ask the person if they have persistent generalized unexplained muscle pain (whether associated with previous lipid-lowering therapy or not).<ul><li>If present, measure CK level:<ul><li>If the CK level is raised but is less than five times the upper limit of normal, start lipid-lowering treatment.</li><li>If the CK level is five or more times the upper limit of normal, re-measure after 7 days. If levels are still five times the upper limit of normal, seek specialist advice (for example from a lipid clinic).</li></ul></li><li>Do not measure CK in asymptomatic people being considered for statin treatment.</li></ul></li><li><strong>Liver function tests (alanine aminotransferase or aspartate aminotransferase) </strong>—<strong> </strong>if these results are abnormal, perform further investigations to determine the cause of the abnormal test results (for example non-alcoholic fatty liver disease).<ul><li>Do not routinely exclude from treatment people who have liver enzymes that are elevated but are less than three times the upper limit of normal.</li></ul></li><li><strong>Renal function (including estimated glomerular filtration rate) </strong>— chronic kidney disease (CKD) does not preclude the use of a lipid-lowering drug. However, specific doses are recommended depending on the stage of CKD. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>.</li><li><strong>HbA1c<sub> </sub></strong>—<strong> </strong>to diagnose diabetes mellitus.<ul><li>An HbA1c<sub> </sub>of 48 mmol/mol is recommended as the cut-off point for diagnosing diabetes mellitus. An HbA1c<sub> </sub>of 42–47 mmol/mol indicates high risk of diabetes mellitus, when lifestyle advice and annual monitoring is recommended. However, lipid-modification treatment should not be stopped due to acute elevations in blood glucose.</li><li>See the sections on lipid modification in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for information on prescribing lipid-modification treatment to a person with diabetes mellitus.</li></ul></li><li><strong>Thyroid stimulating hormone </strong>— to detect a thyroid disorder. <ul><li>Hypothyroidism (primary or secondary) is a recognized cause of dyslipidaemia.</li><li>Untreated hypothyroidism increases the risk of statin-induced myopathy.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li></ul></li></ul><!-- end field cce35e77-0a70-4aff-b2b2-aa0200cc3bea --><!-- end item 14912e4d-96ff-4de1-92cd-aa0200cc3bd5 -->","subChapters":[]},{"id":"1377202f-1876-5844-9834-bbc9f396f718","slug":"basis-for-recommendation-a2e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e2e8daf9-8a3a-4bc2-94dc-031fd7a67261 --><h4>Basis for recommendation</h4><!-- end field e2e8daf9-8a3a-4bc2-94dc-031fd7a67261 -->","summary":null,"htmlStringContent":"<!-- begin item a2ea5fdf-7048-44d9-9255-4ec619b5e53d --><!-- begin field 3839bed6-5cb8-48ed-9c1e-b2661ce8d6b8 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guidelines <em>Identification and management of familial hypercholesterolaemia (Full guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>], <em>Familial hypercholesterolaemia: identification and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>],<em> </em>and <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>].</p><h5>Treatment target </h5><ul><li>The NICE guideline on familial hypercholesterolaemia (FH)<em> </em>recommends a target reduction of low-density lipoprotein (LDL) cholesterol of more than 50% from baseline on the basis of the ASAP study, a randomized, double-blind trial in 325 adults with FH, as this was the therapeutic response associated with lack of progression of atherosclerosis, but advises that clinicians should use their expert judgment when individualizing treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>].</li><li>CKS is aware that this treatment target differs from that in the NICE guideline on lipid modification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>], which gives a treatment aim of 40% reduction in non high-density lipoprotein (HDL) cholesterol. However, NICE has advised that both guidelines are independent of each other as they have a different evidence base formed from a different study population.</li></ul><h5>Baseline tests before starting statin treatment</h5><ul><li>These recommendations are based largely on the NICE guideline on lipid modification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a> for more information.</li></ul><h5>Statin therapy</h5><ul><li>NICE<em> </em>recommends the use of a high-intensity statin in adults with FH, based on limited evidence from a systematic review and a health economic analysis (both commissioned by NICE), as well as evidence from studies in people without FH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>]. <ul><li>In addition, the NICE guideline development group (GDG) considered that because of the high initial concentrations of cholesterol in people with FH, the need to lower concentrations is of great importance, so higher intensity statins may be required to achieve the maximal degree of cholesterol lowering.</li></ul></li><li>NICE does not make specific recommendations on the choice (or dose) of statin but states that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>]:<ul><li>A high-intensity statin with the lowest acquisition cost should be offered as the initial treatment for all adults with FH.</li><li>The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL cholesterol concentration of greater than 50% from baseline.</li></ul></li><li>Statins are classified as high intensity if they produce average reductions in LDL cholesterol greater than 40% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>].<ul><li>According to the NICE guideline <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>], the high-intensity statins available in the UK are atorvastatin 20 mg, 40 mg, and 80 mg; simvastatin 80 mg; and rosuvastatin 10 mg, 20 mg, and 40 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>]. See <a data-hyperlink-id=\"b93da121-f0ef-45c1-8d19-aa03001a9014\" href=\"https://www.nice.org.uk/guidance/cg181/evidence/appendix-a-evidence-summaries-pdf-4724759774\">Appendix A</a> of the NICE guideline <em>Cardiovascular disease: risk assessment and reduction, including lipid modification </em>for more information.</li><li>Based on this classification, CKS recommends starting treatment with atorvastatin 20 mg or rosuvastatin 10 mg. Simvastatin 80 mg is not recommended as a first-line treatment for people with FH due to evidence of an increased risk of myopathy associated with its use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2010</a>].<ul><li>The Medicines and Healthcare products Regulatory Agency (MHRA) advises that simvastatin 80 mg should be considered only in people with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2010</a>].</li></ul></li></ul></li><li>The recommendation regarding the use of rosuvastatin in people aged over 70 years of age, people of Asian origin, and people with stage 3 chronic kidney disease is based on the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">ABPI, 2019</a>]. The manufacturer recommends a lower starting dose of rosuvastatin (that is, 5 mg) in this group of people, but this is a medium-intensity dose.</li></ul><h5>Considering ezetimibe when statins are contraindicated</h5><ul><li>The recommendation to consider ezetimibe if statins are contraindicated is based on the NICE guidelines on FH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>]<em> </em>and the NICE Technology appraisal <em>Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016b</a>].<ul><li>NICE found that ezetimibe was superior to placebo in reducing LDL cholesterol concentrations in adults with primary hypercholesterolaemia in whom statins were considered inappropriate or had not been tolerated. There were no serious adverse events, and there was no difference in adverse event rates between ezetimibe and placebo groups. Although the effects of ezetimibe on cardiovascular mortality or morbidity are unknown, NICE chose reduction of LDL cholesterol concentration as the primary target of drug treatment in people with FH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>].</li></ul></li></ul><!-- end field 3839bed6-5cb8-48ed-9c1e-b2661ce8d6b8 --><!-- end item a2ea5fdf-7048-44d9-9255-4ec619b5e53d -->","subChapters":[]}]},{"id":"4dba1190-9aec-5c55-8089-a315bffcb9dc","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field b6897268-326c-42d9-9a53-39acbbe3a06d --><h3>What follow up is recommended after initiation of lipid-modification treatment?</h3><!-- end field b6897268-326c-42d9-9a53-39acbbe3a06d -->","summary":null,"htmlStringContent":"<!-- begin item 85417e33-d1f2-4a44-acae-1875ae0a2eed --><!-- begin field 35a044dc-ba22-45e1-ba6e-a11b22c28348 --><ul><li><strong>Measure lipid levels after 3 months of statin treatment. The aim of treatment is to achieve a greater than 50% reduction in baseline low-density lipoprotein (LDL) cholesterol levels.</strong><ul><li><strong>If the target has not been reached:</strong><ul><li>Discuss adherence and timing of dose, and reinforce adherence to drug treatment, diet, and lifestyle measures.</li><li>Titrate the dose of the statin (atorvastatin or rosuvastatin) up to the maximum licensed or tolerated dose to achieve the target.</li></ul></li><li><strong>If statin monotherapy fails to achieve the target, </strong>consider one of the following two options:<ul><li>Prescribe ezetimibe 10 mg once daily in addition to a statin. For detailed information on prescribing statins or ezetimibe, including contraindications and cautions, adverse effects, and drug interactions, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/\">Prescribing information</a>.</li><li>Consider prescribing simvastatin 80 mg for people with severe hypercholesterolaemia and high risk of cardiovascular complications.</li></ul></li><li><strong>If combined treatment with a statin and ezetimibe fails to achieve the target, or simvastatin 80 mg is not indicated, </strong>refer to a specialist with expertise in FH. Secondary care treatment options include:<ul><li>Co-administration of a statin and other lipid-lowering drugs (for example a bile acid sequestrant [resin] or a fibrate).</li><li>Trial of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (alirocumab or evolocumab), alone or in combination with a statin and/or other lipid-lowering drugs. See the National Institute for Health and Care (NICE) technology appraisal guidance on <a data-hyperlink-id=\"c079643e-8591-4eb2-896c-a9fa00f062d5\" href=\"https://www.nice.org.uk/guidance/ta393/chapter/1-Recommendations\">Alirocumab</a> and <a data-hyperlink-id=\"8186488d-532a-4324-9ef4-a9fa00f0630c\" href=\"https://www.nice.org.uk/guidance/ta394/chapter/1-Recommendations\">Evolocumab</a> for more informaton on these treatments. </li></ul></li></ul></li><li><strong>Recheck liver function tests (LFTs) within 3 months of starting treatment, and again at 12 months. </strong>Further monitoring is not necessary unless clinically indicated (for example if symptoms or signs of hepatotoxicity develop).</li><li><strong>Offer a regular structured review that is carried out at least annually. </strong>During the annual review:<ul><li>Check medication adherence, and ask about possible adverse effects of treatment.</li><li>Ask about symptoms of coronary heart disease (CHD).<ul><li>In adults, consider doing a baseline electrocardiogram (ECG) if this was not carried out at diagnosis.</li><li>A low threshold for referral is recommended for evaluation of possible CHD symptoms.</li></ul></li><li>Check fasting lipids and blood pressure, and consider checking HbA1c and renal function.</li><li>Consider whether any of the following are needed:<ul><li>Smoking cessation or weight loss advice. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> and <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li>Additional lifestyle advice.</li><li>Change to lipid-modifying drug.</li><li>Pregnancy or contraception <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/statins-atorvastatin-rosuvastatin-simvastatin/#contraindications-cautions\">advice</a>.</li><li>Referral to a specialist with expertise in FH.</li></ul></li></ul></li><li><strong>Routinely monitor for adverse effects of statin treatment.</strong><ul><li>If unexplained muscle symptoms (such as pain, tenderness, or weakness) develop:<ul><li>Check creatine kinase (CK) levels.</li><li>Stop statin treatment immediately if muscle symptoms are intolerable or if CK is five or more times the upper limit of normal.</li></ul></li><li>If muscle pain develops but statin treatment was previously tolerated for more than 3 months, explore other possible causes of myalgia and raised CK, such as vigorous physical activity, hypothyroidism, infection, recent trauma, and drug or alcohol misuse.<ul><li>If the statin is suspected to be the cause of muscle pain and CK is five or more times the upper limit of normal, stop statin treatment immediately.</li></ul></li><li>If other adverse effects are reported, discuss the following possible strategies with the person:<ul><li>Stopping statin treatment and trying again when the symptoms have resolved to check if the symptoms are related to statin use, <em>or</em></li><li>Changing to an alternative <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#basis-for-recommendation-a2e\">high-intensity statin</a> or ezetimibe, <em>or</em></li><li>Referral to a specialist with expertise in FH for consideration of treatment with a bile acid sequestrant (resin) or a fibrate.</li></ul></li></ul></li></ul><!-- end field 35a044dc-ba22-45e1-ba6e-a11b22c28348 --><!-- end item 85417e33-d1f2-4a44-acae-1875ae0a2eed -->","subChapters":[{"id":"3dbcf71f-540d-5134-af2d-7271c919c520","slug":"basis-for-recommendation-39d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b7df48a6-e48c-4dd4-a474-9b7fa9e1cc3f --><h4>Basis for recommendation</h4><!-- end field b7df48a6-e48c-4dd4-a474-9b7fa9e1cc3f -->","summary":null,"htmlStringContent":"<!-- begin item 39de19ef-c3a2-428a-9fe6-3073c828e382 --><!-- begin field ec0006b7-9645-43e3-9130-39e0825bad40 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guidelines <em>Identification and management of familial hypercholesterolaemia (Full guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>], <em>Familial hypercholesterolaemia: identification and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>],<em> </em>and <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>].</p><h5>Measuring lipid levels after 3 months of lipid-modification treatment</h5><ul><li>This recommendation is based on the NICE guideline <em>Cardiovascular disease: risk assessment and reduction, including lipid modification</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>], and aims to assess the efficacy of treatment.</li></ul><h5>Treatment target </h5><ul><li>The NICE guideline on familial hypercholesterolaemia (FH)<em> </em>recommends a target reduction of low-density lipoprotein (LDL) cholesterol of more than 50% from baseline on the basis of the ASAP study, a randomized, double-blind trial in 325 adults with FH, as this was the therapeutic response associated with lack of progression of atherosclerosis, but advises that clinicians should use their expert judgment when individualizing treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>].</li><li>CKS is aware that this treatment target differs from that in the NICE guideline on lipid modification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>], which gives a treatment aim of 40% reduction in non high-density lipoprotein (HDL) cholesterol. However, NICE has advised that both guidelines are independent of each other as they have a different evidence base formed from a different study population.</li></ul><h5>Combining ezetimibe with a statin to reach the treatment target</h5><ul><li>This recommendation is based on the NICE guideline <em>Identification and management of familial hypercholesterolaemia (Full guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>].<ul><li>NICE based this recommendation on evidence from one randomized controlled trial (RCT) in 720 adults with heterozygous FH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Kastelein et al, 2008</a>] and on evidence extrapolated from two systematic reviews of RCTs in adults with heterozygous FH and adults with non-familial hypercholesterolaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Ara et al, 2008</a>]. (The RCT was published after the search date of the systematic review.)</li><li>None of the studies included clinical outcomes, such as cardiovascular morbidity or mortality, but NICE stated that the primary target of drug treatment is reduction in low-density lipoprotein (LDL) cholesterol concentration.</li><li>One systematic review showed an overall safety profile for the combination similar to that of a statin alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Ara et al, 2008</a>], but a subsequent trial found an increased risk of cancer in people taking ezetimibe together with a statin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Rossebo et al, 2008</a>], although this finding was not confirmed in a meta-analysis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Peto et al, 2008</a>].</li></ul></li></ul><h5>When to consider simvastatin 80 mg</h5><ul><li>This recommendation is based on a Medicines and Healthcare products Regulatory Agency (MHRA) warning which highlights the increased risk of myopathy associated with simvastatin 80 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2010</a>].<ul><li>The MHRA advises that simvastatin 80 mg should be considered <em>only </em>in people with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2010</a>].</li></ul></li></ul><h5>Rechecking liver function tests (LFTs) within 3 months of starting treatment, and again at 12 months</h5><ul><li>This recommendation is based on the NICE guideline on lipid modification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>].<ul><li>The NICE guideline development group noted that transaminase elevations usually occur on initiation of statin treatment repeat LFTs are therefore recommended 3 months after initiation, and again at 12 months. Further monitoring is not necessary unless there are other liver comorbidities needing more frequent monitoring.</li></ul></li></ul><h5>Reviewing lipid-modification treatment annually</h5><ul><li>NICE recommends an annual medication review once a person is stable on their tolerated dose of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>].</li><li>The recommendation to consider checking HbA1c<sub> </sub>and renal function is based on what CKS considers to be good clinical practice, as the identification of additional risk factors for coronary heart disease will guide the management (in particular, referral) of adults with FH.</li></ul><h5>Routinely monitoring for adverse effects of lipid-modification treatment</h5><ul><li>These recommendations are based largely on the NICE guidelines on lipid modification [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2016a</a>] and FH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">NICE, 2017a</a>] and are supported by advice issued by the MHRA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2014</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>], and expert opinion in review articles on lipid management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Smellie et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Smellie, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Guyton et al, 2014</a>].</li></ul><!-- end field ec0006b7-9645-43e3-9130-39e0825bad40 --><!-- end item 39de19ef-c3a2-428a-9fe6-3073c828e382 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}